Showing 6211-6220 of 9527 results for "".
DermWire TV: Kysse Approved, Sunscreen Use Trends, AbbVie/Allergan Deal
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwire-tv-kysse-approved-sunscreen-use-trends-abbvieallergan-deal/19812/Galderma's Restylane Kysse is now FDA approved for lip augmentation and the correction of wrinkles around the upper lips in adults. Americans understand that sunscreen use is important to protect the skin, but they still don’t use SPF regularly, AAD data reveal. AbbVie has completed its acquisitionPractical Dermatology Roundtable: Alopecia Areata Burden, Ch. 5
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-alopecia-areata-burden-ch-5/68943/In the fifth installment of this five-part series during Alopecia Areata Awareness Month, host Natasha Atanaskova Mesinkovska, MD, PhD, and guests Maryanne Senna, MD, and Chesahna Kindred, MD, MBA, FAAD, discuss prescribing systemic therapies for pediatric patients with alopecia areata.TBDPractical Dermatology Roundtable: Alopecia Areata Burden, Ch. 3
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-alopecia-areata-burden-ch-3/68941/In the third installment of this five-part series during Alopecia Areata Awareness Month, host Natasha Atanaskova Mesinkovska, MD, PhD, and guests Maryanne Senna, MD, and Chesahna Kindred, MD, MBA, FAAD, discuss the therapeutic options available for alopecia areata and the key factors in selecting aAnalyzing Recent Deuruxolitinib Data
https://practicaldermatology.com/videos/skin-minute/analyzing-recent-deuruxolitinib-data/57165/Arash Mostaghimi, MD, MPH, FAAD, Vice Chair of Clinical Trials and Innovation for the Brigham & Women's Hospital Department of Dermatology, discusses reently released data on deuruxolitinib for the treatment of alopecia areata.Encouraging Conversation
https://practicaldermatology.com/topics/skin-cancer-photoprotection/encouraging-conversation-40-gep-testing-for-adjuvant-radiation-therapy-candidates/37104/Two studies validate the 40-GEP test for identifying patients most likely to benefit from adjuvant radiation therapyHow Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiDermWireTV: Inclusion in Derm; Amgen, Incyte, Janssen, Dermavant Updates; Klisyri Launch; More
https://practicaldermatology.com/topics/practice-management/dermwiretv-inclusion-in-derm-amgen-incyte-janssen-dermavant-updates-klisyri-launch-more/19901/For an article in Pediatric Dermatology, Linda Oyesiku, MPH, a student member of the Society for Pediatric Dermatology, describes historical obstacles to inclusion and highlights opportunities to expand representation and reduce bias in dermatology. Research conducted by The Martec Group using theirExpanding the Role of Topicals in Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-updates-in-atopic-dermatitis/expanding-the-role-of-topicals-in-atopic-dermatitis/57282/Tina Bhutani-Jacques, MD, MAS, discusses how newer nonsteroidal topical therapies are changing the treatment paradigm in atopic dermatitis, expanding options for patients across disease severities and supporting long-term disease management.Atopic Dermatitis in the Real World
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/atopic-dermatitis-in-the-real-world/57014/Emma Guttman, MD, PhD, discusses the disconnect that sometimes exists in atopic dermatitis between clinical trials and real-world situations.Clinical Conversations: Discover Dr J Scott Boswell’s Perspective on Redefining PN and AD Through a Neuroimmune Lens
https://practicaldermatology.com/videos/nemluvio-peer-network/clinical-conversations-discover-dr-j-scott-boswells-perspective-on-redefining-pn-and-ad-through-a-neuroimmune-lens/56421/In this Clinical Conversations newsletter, Dr Scott Boswell shares how reframing prurigo nodularis (PN) and atopic dermatitis (AD) as neuroimmune-driven conditions has shaped his clinical philosophy. He shares his 3‑step approach to patient communication, highlights real‑world treatment journeys in